Nov 13, 2018 | Densitas Inc., News
PRNewswire/ – Densitas, Inc., a breast imaging analytics innovator based in Halifax, Nova Scotia, today announced the signing of a new Alliance Partner Agreement with Blackford. This agreement gives Blackford the right to promote, market, sell, distribute, and license densitasdensity™ directly via integration with the Blackford Platform™. Work will now commence to integrate densitasdensity™ with the Blackford Platform.
“The platform approach will help us bring new products to market more quickly, support our scaling activities, and simplify integration for our customers” says Mohamed Abdolell, CEO of Densitas. “We expect the Blackford Platform to reduce our time to market and shorten our sales cycle as we will be incorporated as an extension of the Blackford Platform infrastructure.”
The densitasdensity™ software provides an automated mechanism for quantifying and recording percent breast tissue density, and making it readily available to the radiologist. Beyond speeding and simplifying the process of quantifying breast density, densitasdensity™ standardizes the density measurement which enables uniform application of risk-based stratification of screen eligible women aimed at ensuring those who need more aggressive follow-up receive it, while those who do not need aggressive follow-up do not receive unnecessary imaging. Densitas software is unique in that it assesses breast density using the routinely archived processed DICOM images that radiologists normally review, and therefore supports prospective and retrospective breast density measurement for clinical care and for research.
Blackford CEO, Ben Panter said this of the alliance:
“We are delighted to add densitasdensity™ to the curated marketplace of applications available through Blackford Platform. We look forward to working with Densitas to provide our customers and channel partners multiple imaging applications that can be easily deployed and maintained.”
densitasdensity™ will be demonstrated at the upcoming Radiological Society of North America (RSNA) 2018 annual meeting in Chicago. Densitas personnel will be available to discuss the benefits and capabilities of density in Booth #3274 – South Hall at RSNA and in the machine learning pavilion, Kiosk #7367W – North Hall.
To learn more about Blackford Platform applications including densitasdensity™, book a demo at RSNA or visit Blackford at Booth #7364.
About Densitas:
Densitas’ vision is to move the needle in breast cancer screening through tailored patient management for sustainable healthcare service delivery and improved outcomes. Densitas develops advanced breast imaging analytics technologies powered by machine learning with the goal to deliver on-demand actionable insights that improve the quality of breast health management. Our products tackle the key challenges facing women’s imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines, and delivery of appropriate care at sustainable costs. Learn more at www.densitas.health and in our virtual press kit.
About Blackford
Blackford provide a single platform to quickly access and manage a curated marketplace of regulatory approved medical image analysis applications and AI algorithms that add clinical value. Easily integrated into existing workflows, the platform provides actionable information that allows healthcare providers to use imaging information smartly and reduce the cost of care, while improving diagnostic confidence and patient outcomes. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors, one of the UK’s leading business angel syndicates. For more information, visit www.blackfordanalysis.com
Contact Information:
Media Contact Densitas:
Alex Morris
[email protected]
647-470-4363
Media Contact Blackford:
Greg Kingston
[email protected]
+44 131 6688 411]]>
Jul 25, 2018 | Densitas Inc., News
Will enable mammography quality improvement and population level stratified breast screening.
HALIFAX, NS., Canada, July 24, 2018 /PRNewswire/ ‑ Densitas, Inc., a breast imaging analytics innovator based in Halifax, Nova Scotia, announces a recently formalized partnership with the Leeds Teaching Hospitals NHS Trust in the UK. The partnership seeks to introduce innovative personalized breast screening technologies, including our DENSITAS|density™ and DENSITAS|quality™ products, into routine clinical workflow. The goal is to ultimately enable population level stratified breast screening and mammography quality improvement and stimulate research in the area of breast health.
“Our partnership with Leeds Teaching Hospitals, NHS Trust is the first of its kind in the UK and represents an alignment of vision that is intended to improve appropriateness of care in breast cancer screening through innovation in technology and service delivery,” says Mohamed Abdolell, CEO of Densitas. “We are excited to collaborate with Dr. Nisha Sharma, Director of Breast Screening, and her team at Leeds Teaching Hospital’s NHS Trust breast screening program to introduce our machine learning powered breast imaging analytics platform into a clinical care setting.”
Breast tissue density is a confirmed independent risk factor for breast cancer in women. The current standard of care in the UK National Health Service is subjective, visual assessment of breast tissue density by the radiologist, if it is performed at all. The Densitas|density™ software provides an automated mechanism for quantifying and recording breast density, and making it readily available to the radiologist, along with the digital mammograms. This will allow the Leeds team to assess breast density for every woman who has a screening mammogram performed. Beyond speeding and simplifying the process of quantifying breast density, Densitas|density™ standardizes the density measurement and enables stratification of screen eligible women to ensure those who need more aggressive follow-up receive it, while those who do not need aggressive follow-up do not receive unnecessary imaging. Densitas software is unique in that it assesses breast density using the routinely archived processed DICOM images that radiologists normally review, and therefore supports prospective and retrospective breast density measurement for clinical care and for research.
Dr Sharma said: “This is a really exciting development for us because it has the potential to make a real difference to the quality of our screening program and ultimately to the health outcomes of women in Leeds. I’m very pleased that the Leeds Breast Screening unit and research team have the opportunity to collaborate with Densitas. This is the foundation for future developments that will improve breast care, so it’s excellent news for women.”
About Densitas:
Densitas, Inc. develops advanced breast imaging analytics technologies powered by machine learning. Our goal is to deliver actionable insights at the point-of-care that improve the quality of breast health management. Our products address the key challenges facing women’s imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines, and delivery of appropriate care at sustainable costs. Learn more at www.densitas.health
For further information: Alex Morris, 647-470-4363
]]>
Jun 25, 2018 | Densitas Inc., News
EY Entrepreneur Of The Year® Awards 2018 Atlantic program.
“Atlantic Canada has always owned a unique identity, but we’re beginning to see the pace of change pick up in the region as it grows to become a globally recognized hub for diverse talent and innovation,” says Gina Kinsman, EY Entrepreneur Of The Year Atlantic Program Director. “That change was evident in this year’s finalists. We saw a rise in the Emerging Entrepreneur category, with more youth displaying their entrepreneurial spirit, as well as more established companies embracing technology to drive productivity and efficiencies.”
Job creation and technology adoption were dominant themes in the 2018 EY Growth Barometer survey results, and the zeitgeist in Atlantic Canada is no different. Atlantic entrepreneurs are breaking the mould to develop new products and services that transform lives, generate wealth and create thousands of jobs along the way. The businesses of this year’s finalists employ almost 3,700 people and see year-over-year growth with a sum of over $1.5 billion in annual revenues.
“Whether you’re an entrepreneur or an established business, the prospects for growth and opportunity in Atlantic Canada are truly limitless,” says Kinsman. “The calibre of companies that come through our program continues to amaze me. I’m excited to see what comes next.”
For 25 years, the EY Entrepreneur Of The Year® Awards program has recognized the achievements of Canada’s entrepreneurial trailblazers — recognizing more than 3,800 finalists and presenting more than 1,000 awards to inspiring Canadian entrepreneurs.
What’s next?
The Atlantic finalists will come together on 4 October 2018 in Halifax, where EY will name one winner in each of the eight categories selected by the independent panel of judges. One of those category winners will be named the overall Atlantic Entrepreneur Of The Year and will later compete with regional winners from Québec, Ontario, Prairies and Pacific for the EY Entrepreneur Of The Year Canada title. The Canadian winner will go on to compete with winners from across the globe for the title of EY World Entrepreneur Of The Year in June 2019.
More information
Follow @EYCanada, #EOY and #EOYAtlantic on Twitter for the latest event updates.
Visit ey.com/ca/eoy for more program details and a complete list of category finalists and gala dates in the regions.
– 30 –
About EY Entrepreneur Of The Year™
EY Entrepreneur Of The Year is the world’s most prestigious business awards program for entrepreneurs. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries. ey.com/eoy
The 2018 Atlantic independent judging panel consists of Douglas Hall, Director, Pattern Energy Group Inc.; Ed Barrett, President, Barrett Corporation; Kent Scales, CEO, Scales Group of Companies; Nora Duke, Executive Vice President, Fortis Group; Robyn Eddy, President, Eddy Group Ltd.; and Toon Nagtegaal, Founder & Owner, THENEXTPHASE.
This year’s program national sponsors are Ici RDI, The TMX Group, The Globe and Mail Inc., Merrill Corporation, Kira Talent, Air Canada and The Printing House Limited. Atlantic regional sponsors are Atlantic Business Magazine and McInnes Cooper.
About EY
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.
For more information, please visit ey.com/ca. Follow us on Twitter @EYCanada.
EY refers to the global organization and may refer to one or more of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.]]>
Mar 2, 2018 | Densitas Inc., News
510(k) clearance of Densitas’ advanced machine learning algorithm empowers radiologists with on-demand actionable information at point-of-care
VIENNA, Austria – March 1 2018 – Breast imaging analytics innovator Densitas Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its machine learning breast density assessment software. The software empowers radiologists with standardized, personalized and automated density reports to optimize women’s breast health and follow-up care decisions.
“Receiving 510(k) clearance marks a significant milestone in our company’s growth as we expand our global reach into the U.S. market with our flagship product,” said Mohamed Abdolell, CEO of Densitas. We are delighted to be entering the largest medical device market in the world, especially as 31 states have passed mandatory breast density notification laws.”
Breast density has been shown to be strongly associated with cancer risk. Densitas has the distinct advantage of facilitating breast density assessments of routinely stored standard processed images and their priors because the technology processes the same standard digital mammograms that radiologists view. This provides a practical solution for integrating breast density into risk-based models in population-based screening.
The software is cleared for clinical use in the U.S., Europe, Canada and Australia, and is the first of several follow-on products. The software is being showcased at the European Congress of Radiology (ECR 2018), booth 114 at the Austria Center Vienna.
About Densitas
Densitas develops advanced imaging analytics technologies powered by machine learning that deliver actionable insights at point-of-care for personalized breast health. Our products address the key challenges facing breast imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines and standards, and delivery of appropriate care at sustainable costs. For more information, visit www.densitas.health.
Contact
Alex Morris
[email protected]
Mobile: 1-647- 470-4363]]>
Mar 1, 2018 | Densitas Inc., Members, News
See original story here
Breast imaging analytics innovator Densitas Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its machine learning breast density assessment software. The software empowers radiologists with standardized, personalized and automated density reports to optimize women’s breast health and follow-up care decisions.“Receiving 510(k) clearance marks a significant milestone in our company’s growth as we expand our global reach into the U.S. market with our flagship product,” said Mohamed Abdolell, CEO of Densitas. We are delighted to be entering the largest medical device market in the world, especially as 31 states have passed mandatory breast density notification laws.”
Breast density has been shown to be strongly associated with cancer risk. Densitas has the distinct advantage of facilitating breast density assessments of routinely stored standard processed images and their priors because the technology processes the same standard digital mammograms that radiologists view. This provides a practical solution for integrating breast density into risk-based models in population-based screening.The software is cleared for clinical use in the U.S., Europe, Canada and Australia, and is the first of several follow-on products. The software is being showcased at the European Congress of Radiology (ECR 2018), booth 114 at the Austria Center Vienna.About Densitas
Densitas develops advanced imaging analytics technologies powered by machine learning that deliver actionable insights at point-of-care for personalized breast health. Our products address the key challenges facing breast imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines and standards, and delivery of appropriate care at sustainable costs. For more information, visit www.densitas.health]]>
Feb 27, 2018 | Densitas Inc., News
See original story here
Densitas Inc. announced today that it has received regulatory clearance for its automated breast density software, DM-Density. DM-Density has received regulatory clearance from the Australian Therapeutic Goods Administration (TGA) and will be available through the EnvoyAI Platform.
Australia has approximately 12 million women and 1.7 million are screened for breast cancer using mammography every two years. Breast cancer is the most commonly diagnosed cancer in Australian women aged 50-74, with 300 new cases for every 100,000 women. Breast cancer is the second most common cause of cancer mortality in Australian women aged 50-74, with approximately 45 deaths per 100,000 women. The Australian Government has increased its commitment to the early detection of breast cancer by recently expanding the BreastScreen Australia target age to include women 70-74.
Phillip Cahill, Director of Diagnostic Imaging Australia, EnvoyAI’s Australian distributor, will launch DM-Density into the Australian market. “We are pleased to be able to offer Densitas’ software in Australia, as it fills a need for radiologists looking for a reliable and standardized breast density solution.
Densitas automatically reads and categorizes each mammogram, determining a patient’s breast density category, in a matter of a few seconds. The deployment of the Densitas algorithm on the Envoy AI platform is a natural fit that radiologists will find to be seamless,” said Mr. Cahill.
“We are excited that doctors and patients in Australia can now benefit from our advanced machine learning algorithms to assess breast density,” said Mohamed Abdolell, CEO of Densitas. “Our entry into the Australian market marks further expansion of our technology globally.”
About Densitas (www.densitas.health) Densitas develops advanced imaging analytics technologies powered by machine learning that deliver actionable insights at point-of-care for high quality personalized breast health. Our products address the key challenges facing breast imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines and standards, and delivery of appropriate care at sustainable costs.
About EnvoyAI (www.envoyai.com) EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI also works with distribution partners to make algorithms on the platform available to a wide footprint of hospitals and, ultimately, to physicians.
ContactAlex Morris]]>
